MX374297B - Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma - Google Patents

Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma

Info

Publication number
MX374297B
MX374297B MX2018009501A MX2018009501A MX374297B MX 374297 B MX374297 B MX 374297B MX 2018009501 A MX2018009501 A MX 2018009501A MX 2018009501 A MX2018009501 A MX 2018009501A MX 374297 B MX374297 B MX 374297B
Authority
MX
Mexico
Prior art keywords
crystalline form
preparation
tlr7 agonist
tlr7
agonist
Prior art date
Application number
MX2018009501A
Other languages
English (en)
Spanish (es)
Other versions
MX2018009501A (es
Inventor
Fei Sun
Ling Yang
Rui Zhao
Yilong Zhou
Yinghu Hu
Zhaozhong Ding
Zheng Wang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2018009501A publication Critical patent/MX2018009501A/es
Publication of MX374297B publication Critical patent/MX374297B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2018009501A 2016-02-05 2017-02-04 Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma MX374297B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610082029.8A CN107043379A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的晶型a、其制备方法和医药用途
PCT/CN2017/072891 WO2017133684A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的晶型a、其制备方法和用途

Publications (2)

Publication Number Publication Date
MX2018009501A MX2018009501A (es) 2018-12-11
MX374297B true MX374297B (es) 2025-03-06

Family

ID=59499348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009501A MX374297B (es) 2016-02-05 2017-02-04 Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma

Country Status (27)

Country Link
US (2) US10442811B2 (https=)
EP (1) EP3412672B1 (https=)
JP (1) JP6889171B2 (https=)
KR (1) KR102393280B1 (https=)
CN (2) CN107043379A (https=)
AR (1) AR107548A1 (https=)
AU (1) AU2017215801B2 (https=)
CA (1) CA3013518C (https=)
CL (1) CL2018002092A1 (https=)
DK (1) DK3412672T3 (https=)
EA (1) EA035951B1 (https=)
ES (1) ES2830443T3 (https=)
HR (1) HRP20201644T1 (https=)
HU (1) HUE051399T2 (https=)
IL (1) IL260968B (https=)
LT (1) LT3412672T (https=)
MX (1) MX374297B (https=)
NZ (1) NZ744884A (https=)
PH (1) PH12018501643A1 (https=)
PL (1) PL3412672T3 (https=)
PT (1) PT3412672T (https=)
SG (1) SG11201806683UA (https=)
SI (1) SI3412672T1 (https=)
TW (1) TWI754629B (https=)
UA (1) UA121161C2 (https=)
WO (1) WO2017133684A1 (https=)
ZA (1) ZA201805186B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2018000112A1 (en) 2015-10-29 2019-10-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN112105620B (zh) * 2018-05-25 2026-02-24 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
WO2020188448A1 (en) * 2019-03-15 2020-09-24 Janssen Sciences Ireland Unlimited Company Toll-like receptor agonists for use in the treatment of hepatitis b
CN113543788B (zh) * 2019-04-23 2023-12-19 正大天晴药业集团股份有限公司 一种tlr7激动剂的固体药物组合物
JP7811014B2 (ja) 2020-03-02 2026-02-04 プロジェニア インコーポレイテッド 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble
CN116322751A (zh) 2020-08-04 2023-06-23 蛋白科技先锋 包含能够动力学控制的佐剂的mRNA疫苗
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
EP2670244B1 (en) * 2011-02-04 2018-04-11 Duquesne University of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) * 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
LT2906563T (lt) * 2012-10-10 2018-06-11 Janssen Sciences Ireland Uc Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui
KR20150085081A (ko) * 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
MX358025B (es) * 2012-11-20 2018-08-02 Glaxosmithkline Llc Star Compuestos novedosos.
US9550785B2 (en) 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
JP6484253B2 (ja) * 2014-05-01 2019-03-13 ノバルティス アーゲー Toll様受容体7アゴニストとしての化合物および組成物
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
CN105367576A (zh) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途

Also Published As

Publication number Publication date
TWI754629B (zh) 2022-02-11
EA035951B1 (ru) 2020-09-04
ES2830443T3 (es) 2021-06-03
US20190040071A1 (en) 2019-02-07
UA121161C2 (uk) 2020-04-10
MX2018009501A (es) 2018-12-11
JP2019505533A (ja) 2019-02-28
TW201728589A (zh) 2017-08-16
CL2018002092A1 (es) 2018-12-07
PL3412672T3 (pl) 2021-01-25
IL260968B (en) 2022-05-01
LT3412672T (lt) 2020-11-10
NZ744884A (en) 2022-09-30
KR102393280B1 (ko) 2022-05-02
DK3412672T3 (da) 2020-10-19
CN108602831B (zh) 2020-11-03
CN108602831A (zh) 2018-09-28
EA201891768A1 (ru) 2019-01-31
EP3412672A4 (en) 2019-07-17
CA3013518A1 (en) 2017-08-10
JP6889171B2 (ja) 2021-06-18
CN108602831B9 (zh) 2020-12-04
HK1259170A1 (zh) 2019-11-29
US10947245B2 (en) 2021-03-16
US20200039988A1 (en) 2020-02-06
ZA201805186B (en) 2024-08-28
AU2017215801A1 (en) 2018-08-23
SG11201806683UA (en) 2018-09-27
PH12018501643A1 (en) 2019-06-03
AU2017215801B2 (en) 2020-09-10
PT3412672T (pt) 2020-11-11
EP3412672A1 (en) 2018-12-12
EP3412672B1 (en) 2020-07-15
US10442811B2 (en) 2019-10-15
KR20180104117A (ko) 2018-09-19
CA3013518C (en) 2022-07-19
WO2017133684A1 (zh) 2017-08-10
AR107548A1 (es) 2018-05-09
SI3412672T1 (sl) 2021-02-26
BR112018015880A2 (pt) 2018-12-26
CN107043379A (zh) 2017-08-15
HRP20201644T1 (hr) 2020-12-25
HUE051399T2 (hu) 2021-03-01

Similar Documents

Publication Publication Date Title
PH12018501643A1 (en) Tlr7 agonist crystalline form a, preparation method and use thereof
ZA201805240B (en) Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses
MX386321B (es) Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-iloxi) metilo) ciclopropanamina, su forma cristalina y sus sales.
MY198066A (en) Method for the preparation of (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
MX2018009502A (es) Metodo para preparar compuesto de pirrolo[3,2-d]pirimidina y sus intermediarios.
MY200328A (en) Kinase inhibitors and uses thereof
JO3644B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MY183123A (en) Synthesis of copanlisib and its di hydrochloride salt
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
MX385672B (es) Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida.
PH12018502246A1 (en) Substituted fused pyrimidinone compounds
MX2017008430A (es) Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
IN2013MU03565A (https=)
MY197130A (en) Tlr7 agonist crystalline form a, preparation method and use thereof
IN2014CH01257A (https=)
IN2013MU03769A (https=)
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
UA89428U (en) 2-(14,15-dioxa-7-azadispirro[5,1,5,2]pentadec -7-yl)ethanol

Legal Events

Date Code Title Description
FG Grant or registration